Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefixime + ornidazole
- Development stage
- Unknown
- Lead developer
- Neiss Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cefexy-OZ is an oral fixed-dose combination of the third-generation cephalosporin antibiotic cefixime and the nitroimidazole antiprotozoal and antibacterial agent ornidazole. Developed by Neiss Labs, it is marketed in India for the treatment of mixed bacterial and protozoal infections, including respiratory, gastrointestinal, gynecological, urinary tract, skin and soft tissue, and dental infections. Cefixime exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs), thereby inhibiting bacterial cell wall synthesis and causing cell lysis. Ornidazole undergoes reductive activation within anaerobic microorganisms, generating reactive intermediates and free radicals that interact with microbial DNA, causing strand breakage and inhibiting nucleic acid synthesis. Together, the two agents provide synergistic, broad-spectrum antimicrobial coverage.
- Brand names
- Cefexy-OZ
- Other names
- Cefexy OZcefixime + ornidazole
02
Targets
TOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)NeuraminidasePBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on cefixime + ornidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefixime + ornidazole.